Historical source coverage
6 selected records with a cited source date in 2000. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Literature metadata · Glucagon
PeptideScanner retained PubMed bibliographic metadata for PMID 5198467 at 2026-07-30T23:27:29.856Z. PubMed recorded a metadata revision date of 2000-12-18 and an Entrez history date of 1970-02-01. PeptideScanner associated this retained record with the identity slug glucagon. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Glucagon
PeptideScanner retained PubMed bibliographic metadata for PMID 5501122 at 2026-07-30T23:27:29.856Z. PubMed recorded a metadata revision date of 2000-12-18 and an Entrez history date of 1970-01-01. PeptideScanner associated this retained record with the identity slug glucagon. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Glucagon
PeptideScanner retained PubMed bibliographic metadata for PMID 801696 at 2026-07-30T23:27:29.851Z. PubMed recorded a metadata revision date of 2000-12-18 and an Entrez history date of 1976-01-01. PeptideScanner associated this retained record with the identity slug glucagon. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Leuprolide
The official Drugs@FDA dataset lists original submission 1 for ANDA 075471 with status AP dated 2000-10-25, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Leuprolide
The official Drugs@FDA dataset lists original submission 1 for NDA 021088 with status AP dated 2000-03-03, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Glucagon
The Federal Register published notice 00-1872, attributed to FDA and its parent HHS department, on 2000-01-27. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GlucaGen®,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
Source: Federal Register via GovInfo ↗